Sector Expert: Russell Stanley

Echelon Wealth Partners

Image: Russell Stanley

Russell Stanley, analyst at Echelon Wealth Partners, is a special situations analyst whose primary focuses are industrial products and energy services. Prior to joining Echelon Wealth, he worked with Mackie Research and Jennings Capital Inc. He received his master's degree in business administration (Finance and Strategy) from the Schulich School of Business, York University, and is a CFA charterholder.



Recent Interviews

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital (12/23/15)
fist-full-of-dollars630

The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance. In this interview with The Life Sciences Report, Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions. Stanley offers three names that, based on his current target prices, offer investors potential returns of more than 100%.

Keep Truckin': Russell Stanley on How to Snap Up Growing Energy Services Companies (9/25/14)
frozenoilrig580

energy servicesThe oil and gas fields in western Canada are sucking up rental equipment, trucking services and well site accommodation services like the proverbial black hole. Russell Stanley of Jennings Capital, an expert on mergers and acquisitions, knows how to find the margin in the increasingly profitable energy service industry, and explains the rules of this investment game to The Energy Report.

Recent Quotes

"We view HLTH's results as demonstrating solid sequential improvement in terms of margins, receivables collection and financial reporting timeliness."

— Russell Stanley, Mackie Research Capital (8/4/16)
more >

"HLTH's [Q2/16] results demonstrated sequential revenue and EBITDA improvement from Q1/16 levels, reflecting seasonality in the business."

— Russell Stanley, Mackie Research Capital (8/3/16)
more >

"We like HLTH's acquisition of Arizona Vein & Vascular Center, as it expands the company's presence in Arizona and augments the service breadth."

— Russell Stanley, Mackie Research Capital (8/2/16)
more >

"We view Mr. Ken Efird's appointment positively, as it represents a promotion-from-within HLTH for a very capable executive."

— Russell Stanley, Mackie Research Capital (7/11/16)
more >

"HLTH is an undervalued play on growing demand for high acuity surgery in the U.S."

— Russell Stanley, Mackie Research Capital (5/25/16)
more >

"HLTH is an undervalued play on growing demand for high acuity surgery; it's a Buy."

— Russell Stanley, Mackie Research Capital (5/3/16)
more >

"HLTH is an undervalued, overlooked play on growing demand for high acuity surgical procedures."

— Russell Stanley, Mackie Research Capital (3/28/16)
more >

"HLTH's change to now consider 'distressed asset' deals is positive."

— Russell Stanley, Mackie Research Capital (3/17/16)
more >

more comments

"HLTH reported Q4 results that beat our estimates for revenue."

— Russell Stanley, Mackie Research Capital (3/16/16)
more >

"HLTH's timely Q4/15 reporting should further derisk the stock."

— Russell Stanley, Mackie Research Capital (3/11/16)
more >

"Recently, HLTH's CEO acquired 31.7K shares, and other insiders, 21K."

— Russell Stanley, Mackie Research Capital (2/2/16)
more >

"HLTH's reiteration of FY16 guidance is a strong positive."

— Russell Stanley, Mackie Research Capital (1/20/16)
more >

"HLTH currently trades at a discount that is unreasonably high."

— Russell Stanley, Mackie Research Capital (1/15/16)
more >

"HLTH is likely to announce an acquisition in Q1/16."

— Russell Stanley, Mackie Research Capital (1/14/16)
more >

"HLTH's release of its financials should be a major lift to the stock."

— Russell Stanley, Mackie Research Capital (1/13/16)
more >

"Potential catalysts for HLTH include the Q3/15 results and M&A."

— Russell Stanley, Mackie Research Capital (1/8/16)
more >

"HLTH management's breakdown of restatement items is a silver lining."

— Russell Stanley, Mackie Research Capital (1/6/16)
more >

"HLTH gives investors access to a market that's otherwise predominately privately held."

The Life Sciences Report Interview with Russell Stanley (12/23/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.